You are here

Lemtrada Can Cause Serious, But Rare, Risk of Stroke and Tears in Artery Lining

Patients with MS Suffered Stroke, Blood Vessel Tearing in Head and Neck After Receiving Drug

The FDA has issued a warning about potential stroke and tears in the lining of head and neck arteries, which occurred in some patients after receiving Lemtrada (alemtuzumab, Genzyme).  Stroke and tears can potentially lead to permanent disability and even death. The agency has added a new warning about these risks to the drug’s prescribing information and the patient medication guide, and it has also added the risk of stroke to the existing boxed warning.

Alemtuzumab is also available as Campath, which was approved in May 2001 for treating B-cell chronic lymphocytic leukemia (B-CLL). The Campath label will also be changed to include these risks in the adverse reactions section.

Health care professionals are advised to tell patients at every Lemtrada infusion to seek immediate emergency medical attention if they experience symptoms of ischemic or hemorrhagic stroke or cervicocephalic arterial dissection. As early symptoms such as headache and neck pain are not specific, diagnosis can be complicated. Prompt evaluation of patients who complain of symptoms that are consistent with stroke or arterial dissection is recommended.

Most patients who developed stroke or tears in their artery linings had symptoms within one day of being treated with alemtuzumab.

Source:, November 28, 2018

Recent Headlines

Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs